Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes 57:525-526, 2008
DOI: 10.2337/db07-1409
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fousteri, G.
Right arrow Articles by von Herrath, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fousteri, G.
Right arrow Articles by von Herrath, M.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Commentary

First-Trimester Human Fetal Pancreas Transplantation for Type 1 Diabetes Treatment

An Alternative Approach for Achieving Long-Term Graft Survival?

Georgia Fousteri, and Matthias von Herrath

From the La Jolla Institute for Allergy and Immunology, La Jolla, California

Address correspondence and reprint requests to Matthias von Herrath, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037. E-mail: matthias@liai.org

Abbreviations: MHC, major histocompatibility complex; PBMC, peripheral blood mononuclear cell; Treg, regulatory T-cell

The first 20% of the full text of this article appears below.

Type 1 diabetes results from immune-mediated destruction of insulin-producing β-cells of the pancreas. The disease manifests itself symptomatically when the resident β-cells become unable to maintain normoglycemia. In human insulitis, mainly CD8 lymphocytes and B-cells, but also CD4 cells and activated antigen-presenting cells (APCs), are found (1–3). Strikingly, strong upregulation of MHC class I molecules and type 1 interferons have also been observed in noninfiltrated islets from human type 1 diabetic patients, making the involvement of a viral β-cell infection a feasible scenario in terms of disease pathogenesis (4). Among treatments that are currently being evaluated for stable reversal of type 1 diabetes, pancreas or islet transplantation holds promise, since it provides already diabetic patients with new functional β-cells. The routine clinical use of pancreas or isolated intrahepatic islet transplantation is, however, hampered predominantly by the lack of sufficient donor tissue. In addition, islets injected into the portal vein are often lost after 4–5 years, even under optimized immunosuppressive regimens (5), which renders whole pancreas or combined pancreas-kidney transplants important therapeutic alternatives (6).

With this setting, human fetal pancreas derived from therapeutic termination of pregnancies as an alternative source of β-cells has increasingly become an attractive alternative. Potential advantages include its greater proliferative capacity and maturation . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article:

Reduced Immunogenicity of First-Trimester Human Fetal Pancreas
Kerstin Brands, Emily Colvin, Lindy J. Williams, Rennian Wang, Richard B. Lock, and Bernard E. Tuch
Diabetes 2008 57: 627-634. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.